MIDAS Research Initiates Coverage of Biophan Technologies, Inc.

Aug 10, 2005, 01:00 ET from MIDAS Research GmbH

    MANNHEIM, Germany, August 10 /PRNewswire/ -- MIDAS Research has published
 a research report on the nano-medical technology company Biophan
 Technologies, Inc. (OTC BB: BIPH, Frankfurt: BTN) with a 12 month target
 price per share of USD 4.20 and a buy recommendation. A copy of the report is
 available in both German and English at www.midasresearch.de .
     Biophan Technologies, Inc. develops, acquires, and markets technology
 solutions (patents) that solve significant problems arising when patients
 with implanted devices require magnetic resonance imaging (MRI) diagnostics.
 Currently, patients with implanted devices are denied the highly effective
 MRI procedure, as MRI can adversely affect the functioning of implanted
     In the opinion of MIDAS Research analyst Curtis Schneekloth, CFA, Biophan
 correctly belongs to the most discussed nanotech equities both in the USA and
 in Germany. In contrast to other nanotech stocks, the share price potential
 is already backed up to a large extent by a recent business agreement with
 Boston Scientific Corp., a market leader in coronary vessel implants (stents).
     MIDAS Research is an independent stock research company with a global
 focus on emerging industries and undervalued small caps particularly in the
 field of life sciences. Recent reports have successfully highlighted stocks
 like MorphoSys (GER), Mologen (GER), DuraVest (USA) or Dermisonics (USA).
     For further contacts:
     Michael Drepper